While the former Biden administration showcased the Inflation Reduction Act as a key victory in the fight over high drug ...
JMP Securities maintained a positive outlook on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), reiterating a Market Outperform ...
JMP Securities initiated coverage on Kalvista Pharmaceuticals Inc (NASDAQ: KALV), assigning a Market Outperform rating and setting a price target of $19.00. Currently trading at $8.77, the stock has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback